
A new identity for an innovative future
As of February 3, 2025, Baxter’s Kidney Care segment transforms into Vantive, an independent company specializing in vital organ therapies. This change follows the acquisition by funds managed by the global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX).
With over 70 years of experience in renal therapy innovation, Vantive continues its mission to improve patients’ quality of life and offer new therapeutic solutions worldwide.
A constant commitment to patient health
Every day, over 1 million interactions with patients in more than 100 countries highlight Vantive’s pivotal role in supporting individuals undergoing dialysis treatments and life-saving therapies. Currently, about 4 million peopleworldwide require dialysis for chronic kidney failure, navigating a complex physical and emotional journey.
Vantive is committed to removing barriers that limit access to and continuity of care, improving therapeutic solutions for patients and healthcare professionals.
Innovation and technology in healthcare
Vantive develops advanced technologies, innovative digital solutions, and specialized services for:
- Peritoneal dialysis and hospital dialysis;
- Treatment of kidney failure and other vital organ conditions in intensive care;
- Optimizing patient care through remote monitoring tools and digital therapy management.
Vantive’s technology for remote monitoring of peritoneal dialysis patients has been associated with reduced mortality, fewer hospitalizations, and better treatment adherence.
Vision and leadership for the future
Chris Toth, CEO of Vantive, emphasized the importance of this transition:
“From patients starting their dialysis journey to doctors working in intensive care, having the right treatment at the right time is crucial. Our goal is to provide better solutions and new opportunities for those facing these challenges. We are entering a new era of innovation, and I am excited to do so alongside our 23,000 employees who work daily to make a difference in the lives of patients and their families.”
Kieran Gallahue, Chairman of the Vantive Board of Directors, added:
“Vantive marks a significant evolution in renal and vital organ therapies. We offer tools to enhance the connection between patients and healthcare providers, optimize treatment pathways, and make the care experience more effective and accessible.”
Robert Schmidt, Co-Head of Global Healthcare at Carlyle, also confirmed the firm’s commitment to supporting Vantive’s growth:
“We are excited to partner with Vantive to expand its global impact, improve access to care, and enhance the efficiency of treatments for both patients and healthcare professionals.”
Conclusion
The birth of Vantive marks a new chapter in the field of renal and vital organ therapies. With its decades of experience, cutting-edge technology, and an unwavering commitment to innovation, the company aims to transform the industry and significantly improve the lives of millions of patients worldwide.
📢 What do you think about this transformation? Share your opinion in the comments below!